Literature DB >> 12854942

Olanzapine for intractable nausea in palliative care patients.

W Clay Jackson1, Laura Tavernier.   

Abstract

Nausea is a common problem among palliative care patients, which is often undertreated. Olanzapine, an atypical antipsychotic, possesses a unique neurotransmitter binding profile that is similar to methotrimeprazine, an anti-emetic widely used in Europe for recalcitrant nausea. We report a case series of six patients who suffered nausea which was resistant to initial treatment with traditional antiemetics; each patient exhibited marked improvement when treated with olanzapine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12854942     DOI: 10.1089/109662103764978506

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  19 in total

1.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.

Authors:  Sierra Vig; Laurel Seibert; Myke R Green
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-31       Impact factor: 4.553

Review 2.  Nausea and Vomiting in Advanced Cancer.

Authors:  Rudolph M Navari
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

3.  Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.

Authors:  Isseki Maeda; Eriko Satomi; Daisuke Kiuchi; Kaoru Nishijima; Yoshinobu Matsuda; Akihiro Tokoro; Keita Tagami; Yoshihisa Matsumoto; Akemi Naito; Tatsuya Morita; Satoru Iwase; Hiroyuki Otani; Takuya Odagiri; Hiroaki Watanabe; Masanori Mori; Yosuke Matsuda; Hiroka Nagaoka; Meiko Mayuzumi; Yoshiaki Kanai; Nobuhiro Sakamoto; Keisuke Ariyoshi
Journal:  Support Care Cancer       Date:  2021-03-20       Impact factor: 3.603

Review 4.  Opioids and GI Motility-Friend or Foe?

Authors:  Allen A Lee; William L Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 5.  Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

Authors:  Paul Glare; Glenn Pereira; Linda J Kristjanson; Martin Stockler; Martin Tattersall
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

6.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

Review 7.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 8.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.

Authors:  Rudolph M Navari; Marie C Brenner
Journal:  Support Care Cancer       Date:  2009-09-11       Impact factor: 3.603

10.  Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.

Authors:  Zhonghan Zhang; Yaxiong Zhang; Gang Chen; Shaodong Hong; Yunpeng Yang; Wenfeng Fang; Fan Luo; Xi Chen; Yuxiang Ma; Yuanyuan Zhao; Jianhua Zhan; Cong Xue; Xue Hou; Ting Zhou; Shuxiang Ma; Fangfang Gao; Yan Huang; Likun Chen; Ningning Zhou; Hongyun Zhao; Li Zhang
Journal:  Oncologist       Date:  2018-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.